NEW YORK, March 9, 2026, 11:02 EDT
Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%.
This is significant: Atara remains in pursuit of a U.S. route for EBVALLO, also known as tabelecleucel, a cell therapy targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The condition—rare, frequently deadly—can turn up after organ or stem-cell transplants, and, right now, there are no approved therapies for it in the U.S.
Atara and its partner Pierre Fabre said on March 3 they’d requested a Type A meeting with the FDA, typically called when a program is stalled or facing key safety questions, after the regulator turned down the therapy in January. Pierre Fabre maintained that the ALLELE study met requirements and supplemented the agency briefing with longer-term efficacy as well as European post-marketing data, aiming for a possible resubmission.
Wall Street’s reaction has been wider than just reading the headlines. Leerink’s Joseph Schwartz said Sunday that sentiment is likely to “improve materially.” Stifel’s Paul Matteis described the move as “a big win for biotech, especially for companies in the rare disease space.” MarketWatch
Vinay Prasad, the FDA’s Center for Biologics Evaluation and Research chief and the focal point of the current debate, is set to depart in April. RBC Capital’s Brian Abrahams called the exit “likely to be received positively,” though he cautioned that further leadership turnover may continue to cloud the agency’s direction for developers. Fierce Biotech
High stakes for Atara. In January, the FDA shot down the company’s application, arguing the data fell short on proof of effectiveness, despite Atara’s insistence that the agency had previously signed off on the trial design. Shares plunged 56% in a single session.
On March 3, Chief Executive Cokey Nguyen said Atara and Pierre Fabre wanted a “constructive discussion” with the FDA, noting that patient groups and physicians had advocated for the therapy. The U.S. filing was handed off to Pierre Fabre last November, placing the regulatory campaign in the hands of the French firm’s American division. Atara Biotherapeutics
Atara’s financial cushion is thin. As of January, the company reported just $8.5 million in cash and short-term investments projected for the close of 2025, following a drastic staff reduction of about 90% year over year. Most tab-cel costs and development have now been handed off to Pierre Fabre.
Atara caught a break on Feb. 23 after healthcare royalty player HCRx agreed to move a $9 million lump-sum payment deadline to Jan. 1, 2028. That extension helps, but it doesn’t lock in a turnaround. The FDA still hasn’t named anyone to replace Prasad, and there’s no promise a Type A meeting will sway the agency.
Monday’s action pointed to traders weighing regulatory sentiment as heavily as Atara’s fundamentals. The next steps hinge on the FDA meeting—if the upcoming review team pushes for additional data, not a lighter touch, that could be crucial.
